Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 14;56(4):932–944. doi: 10.3892/ijo.2020.4987

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Chen et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Patients with TAM-resistance have favorable remission rates in response to cisplatin-based chemotherapy. (A) Summary of endocrine therapies administered to 178 patients with ER⁺ recurrent and metastatic breast cancer. A total of 122 patients were determined to exhibit TAM resistance. (B) Chemotherapy regimens and responses in 125 patients with ER⁺ recurrent and metastatic breast cancer. Clinical responses were evaluated in comparison with alteration of target lesions during chemotherapy. (C) Clinical remission rates of TAM-resistant patients administered different chemotherapy regimens. (D) Clinical remission rates of patients administered cisplatin-based chemotherapy following treatment with different endocrine-therapy regimens. C, cyclophosphamide; E, epirubicin; F, fluorouracil; T, paclitaxel; N, vinorelbine; G, gemcitabine; P, cisplatin; PR, partial response; SD, stable disease; PD, progressive disease; UN, unknown; ER⁺, estrogen receptor-positive; TAM, tamoxifen.